Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events

American Journal of Pathology

Volumn 162, Issue 5, 2003, Pages 1449-1461

  Quintanilla Martinez, Leticia ^a   Kremer, Marcus ^a,b   Specht, Katja ^a,b   Calzada Wack, Julia ^a   Nathrath, Michaela ^a   Schaich, Robert ^a   Höfler, Heinz ^b   Fend, Falko ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 0037408535     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64278-2     Document Type: Article

References (31)

1. Darnell Jr JE: STATs and gene regulation. Science 1997, 277: 1630-1635
2. Bromberg J, Darnell Jr JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473
3. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to embryonic lethality. Proc Natl Acad Sci USA 1997, 94:3801-3804
4. O'Shea JJ, Gadina M, Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109:121-131
5. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 2000, 19:2474-2488
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE: Stat3 as an oncogene. Cell 1999, 98:295-303
7. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nuñez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115
8. Puthier D, Bataille R, Amiot M: IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999, 29:3945-3950
9. Zhang B, Gojo I, Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002, 99:1885-1893
10. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R, Amiot M: Mcl-1 and Bcl-xl are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999, 107:392-395
11. Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21
12. Pruneri G, Fabris S, Balsini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A: Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000, 156:1505-1513
13. Wilson CS, Butch AW, Lai R, Medeiros J, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK: Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol 2001, 112:776-782
14. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ: The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000, 113: 831-837
15. Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK: Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997, 10:927-932
16. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp M-J, Harousseau J-L, Minvielle S, Bataille R, for the intergroupe Francophone du Myelome: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191
17. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W: Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol 1987, 87:342-355
18. Durie BGM, Salmon S: A clinical staging system for multiple myeloma. Cancer 1975, 36:842-854
19. Specht K, Kremer M, Müller U, Dirnhofer S, Rosemann M, Höfler H, Quintanilla-Martinez L, Fend F: Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time RT-PCR of microdissected paraffin sections. Clin Cancer Res 2002, 8:2902-2911
20. Specht K, Richter T, Müller U, Walch A, Werner M, Höfler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001, 158:419-429
21. Ogata A, Chauhan D, Urashima M, Teoh G, Treon S, Anderson KC: Blockade of MAPK cascade signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res 1997, 3:1017-1022
22. Chatterjee M, Hönemann D, Lentzsch S, Bommert K, Sers C, Hermann P, Mathas S, Dörken B, Bargou RC: In the presence of bone marrow stromal cells human multiple myeloma cells become independent of IL-6/gp130/Stat 3 pathway. Blood 2002, 100:3311-3318
23. Derenne S, Monia B, Dean NM, Taylor JK, Rapp M-J, Harousseau J-L, Bataille R, Amiot M: Antisense strategy shows that Mcl-1 rather that Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199
24. Puthier D, Pellat-Deceunynck C, Barillé S, Robillard N, Rapp M-J, Juge-Morineau N, Harousseau JL, Bataille R, Amiot M: Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy Leukemia 1999, 13:289-294
25. Ong F, van Nieuwkoop JA, de Groot-Swings GM, Hermans J, Harvey M, Kluin P, Kluin-Nelemans J: Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995, 9:1282-1284
26. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC: Immunohistochemical analysis of Mcl-1 protein in human tissues Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995, 146:1309-1319
27. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L, Reed JC: Immunohistochemical analysis of in vivo patterns of Bcl-xl expression. Cancer Res 1994, 54:5501-5507
28. Bienvenu F, Gascan H, Coqueret O: Cyclin D1 represses Stat 3 activation through a Cdk4-independent mechanism. J Biol Chem 2001, 276:16840-16847
29. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002, 62:3351-3355
30. Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES, Raffeld M: Mantle cell lymphomas lack expression of p27, a cyclin dependent kinase inhibitor. Am J Pathol 1998, 153:175-182
31. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997, 94:6380-6385